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ABSTRACT
Cell cycle-dependent gene expression is often con-
trolled on the transcriptional level. Genes like cyclin
B, CDC2 and CDC25C are regulated by cell cycle-
dependent element (CDE) and cell cycle genes
homology region (CHR) promoter elements mainly
through repression in G0/G1. It had been suggested
that E2F4 binding to CDE sites is central to tran-
scriptional regulation. However, some promoters
are only controlled by a CHR. We identify the
DREAM complex binding to the CHR of mouse and
human cyclin B2 promoters in G0. Association of
DREAM and cell cycle-dependent regulation is
abrogated when the CHR is mutated. Although
E2f4 is part of the complex, a CDE is not essential
but can enhance binding of DREAM. We show that
the CHR element is not only necessary for repres-
sion of gene transcription in G0/G1, but also for ac-
tivation in S, G2 and M phases. In proliferating cells,
the B-myb-containing MMB complex binds the CHR
of both promoters independently of the CDE.
Bioinformatic analyses identify many genes which
contain conserved CHR elements in promoters bind-
ing the DREAM complex. With Ube2c as an example
from that screen, we show that inverse CHR sites
are functional promoter elements that can bind
DREAM and MMB. Our findings indicate that the
CHR is central to DREAM/MMB-dependent tran-
scriptional control during the cell cycle.
INTRODUCTION
The expression of many genes that play a central role in
the cell cycle is regulated on the transcriptional level. They
are characterized by a cyclic expression during different
phases of the cell cycle. Genes expressed at the G1/S tran-
sition are often regulated by complexes formed by E2F
transcription factors, their dimerization partners DP1 or
DP2, and the pocket proteins pRB, p130 or p107 (1–3).
While the regulation of these S phase genes is well under-
stood, many open questions remain for the regulation of
genes with a maximal expression in late S, G2 or M phases.
Many of these genes like cyclin B, CDC25C, CDC2, CKS1
and aurora kinase B are repressed in the early phases
of the cell cycle by unknown mechanisms. However, the
promoters of these genes appear to share some com-
mon features. Most strikingly, phylogenetically con-
served cell cycle-dependent element (CDE) and cell cycle
genes homology region (CHR) sites and CCAAT-boxes
can often be found close to the transcription start in the -
promoters of such genes. While CDE and CHR medi-
ate transcriptional repression in early cell cycle phases,
the CCAAT-boxes are necessary for transcriptional
activation (4).
The CDE was ﬁrst observed by in vivo footprinting in
the human CDC25C promoter to be protected during G0
(5). Mutation of this element and subsequent analysis of
the promoter in reporter assays revealed that the CDE is
important for transcriptional repression in early cell cycle
phases. Soon after this observation, another element, then
named the CHR, was discovered by sequence comparison
and functional analysis of the CDC25C, cyclin A2 and
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sequence TTTGAA. Its mutation leads to a loss of tran-
scriptional repression in G0 and G1 phases as observed for
the CDE site. Further analysis provided evidence that the
CDE and the CHR always appear in close proximity with
a spacer of four nucleotides. The sequence of the CDE is
rich in guanine and cytosine and is related to the TTGGC
GC E2F-binding consensus. Consistent with a similarity
of CDE and E2F sites, binding of E2F and pocket
proteins was shown to several CDE-regulated promoters,
e.g. CDC2, cyclin A2 and aurora kinase B (6–9).
However, a similarity between E2F- and CDE-
dependent regulations would not explain the necessity of
CHRs in CDE/CHR-controlled genes. Assuming that pro-
tein binding is required for CHR function, one would
speculate that CDE and CHR elements cooperate in
protein binding. Consistently, it was observed for the
CDC2 promoter that E2F4 binding to the CDE is abol-
ished after mutating the CHR (6,10). This result may be
explained by proteins associated with the CHR being es-
sential for E2F4 binding to the CDE. Several groups tried
to identify the factors binding to CHRs responsible for
regulating different genes. For the cyclin A2 promoter, a
protein named CHF has been observed to bind to the
CHR in EMSAs (11). Another factor that was called
CDF-1 was found to associate with the CDE/CHR
elements in CDC25C and CCNA2 promoters (12,13).
However, cloning or further characterization of any of
these factors was not accomplished.
The link between CDE and CHR regulation and
protein binding becomes more puzzling when genes like
mouse Cdc25C, human cyclin B1, cyclin B2 and PLK1 are
considered. Their promoters have been shown by sequence
comparison and mutation analyses to be controlled by a
single CHR without additional CDE or E2F site (14–18).
Thus, central questions remain open as to which proteins
are binding to the CDE and/or the CHR elements and
how these proteins control transcriptional repression of
genes in the early cell cycle phases.
Here, we observe that the DREAM (DP, RB-like, E2F4
and MuvB) complex binds to the CHR of mouse and
human cyclin B2 promoters in G0. Mutation of the
CHR in both promoters results in a complete loss of
DREAM complex binding and deregulation of the pro-
moters in the cell cycle. Although E2F4 is part of the
complex in G0 and early G1 phase (19–21), an E2F-like
CDE element is not essential for DREAM binding.
However, the CDE in the mouse cyclin B2 promoter can
support binding of the DREAM complex. Surprisingly,
we ﬁnd that the CHR is not only necessary for suppres-
sion of promoter activity, but also for activation. In
proliferating cells, the B-myb-containing MMB (Myb-
MuvB) complex binds to the CHR of both promoters in-
dependently of the CDE. Additionally, bioinformatic
analyses of experimental data identify many more genes
which bind the DREAM complex and contain evolution-
ary conserved CHR elements in their promoters. We
prove that this approach is applicable for the identiﬁcation
of promoters with functional CHR elements by showing
that the mouse Ube2c promoter binds the DREAM and
MMB complexes through an inverse CHR that is essential
for the regulation of cell cycle-dependent expression. Our
ﬁndings indicate that the CHR is a central element in
many promoters mediating transcriptional regulation in
the cell cycle by the DREAM and MMB complexes.
MATERIALS AND METHODS
Cell culture
NIH3T3 and F9 cells obtained from DSMZ
(Braunschweig, Germany) were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Lonza, Basel,
Switzerland) supplemented with 10% fetal calf serum
(FCS) and penicillin/streptomycin. Cells were maintained
at 37 C and 10% CO2. F9 cells were grown on 0.1%
gelatin-coated dishes.
For synchronization in G0 phase, NIH3T3 cells were
either density arrested for 3–4 days or arrested by serum
starvation (DMEM with 0% FCS) for 60h. To analyze
cells during their passage through the cell cycle, they were
restimulated with 20% FCS in DMEM after the
serum-deprivation phase.
Stably transfected NIH3T3 cell lines were created by
transfecting promoter–reporter constructs based on the
pGL4.14-Hygro vector (Promega, Madison, WI, USA)
and selection with hygromycin (PAA, Linz, Austria) at a
concentration of 500mg/ml.
For SILAC analysis, NIH3T3 cells were grown in
DMEM minus arginine and lysine (Thermo Fisher
Scientiﬁc, Rockford, IL, USA) supplemented with 10%
FCS and penicillin/streptomycin (PAA, Linz, Austria).
To produce the ‘light’ media, L-arginine–HCl and
L-lysine–HCl were added to a ﬁnal concentration of
84mg/ml and 146mg/ml, respectively, whereas
13C6,
15N4
L-arginine–HCl and
13C6 L-lysine–HCl (Thermo Fisher
Scientiﬁc) were applied at the same concentrations to
obtain the ‘heavy’ medium.
Plasmids and DNA probes
The human cyclin B2 promoter (nt  903 to+1 relative to
translational start, designated as hCCNB2-long) has been
described before (17). hCCNB2 wt, hCCNB2 ‘CDE’mut,
hCCNB2 CHRmut and hCCNB2 ‘CDE’/CHRmut were
cloned in the pGL4.10 vector. hCCNB2-short was
produced by PCR ampliﬁcation creating promoter frag-
ments with a size of 263nt (nucleotides  262 to +1)
followed by ligation into the pGL4.10 or pGL4.14
vectors (Table 1).
The mouse cyclin B2 promoter with a size of 1190bp (nt
 1189 to+1, named mCcnb2-long) and the mouse Ube2c
promoter (nt  478 to  3) were ampliﬁed from genomic
NIH3T3 cell DNA and cloned in the pGL4.10 vector.
mCcnb2-short was produced by PCR ampliﬁcation cre-
ating promoter fragments with a size of 210nt (nt  209
to +1) and subsequent ligation in pGL4.10 or pGL4.14
vectors. Mutations were introduced with the QuikChange
site-directed mutagenesis kit (Agilent Technologies,
Santa Clara, CA, USA) (Table 1). Plasmids used for
B-myb-knockdown (sh-Bmyb1, sh-Bmyb2) were kind gifts
from Kenneth Boheler (22). DNA probes for afﬁnity puri-
ﬁcation with the same sequence as hCCNB2-short and
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without CCAAT-boxes (nt  130 to +1) were obtained
by PCR using a biotinylated primer for labeling the
30-end (Invitrogen, Carlsbad, CA, USA). As a negative
control, a fragment of the mouse Gapdhs promoter (nt
 169 to +12 relative to the transcription start site) was
used. Sequences of primers are available in the
Supplementary Methods.
DNA afﬁnity puriﬁcation
For DNA afﬁnity puriﬁcation of protein complexes in G0
cells, NIH3T3 cells were grown to conﬂuence and density
arrested for three additional days. F9 cells were grown to
80–90% conﬂuence. Cells were washed with PBS, scraped
and centrifuged. Nuclei were isolated by incubation for
10min in buffer A [10 mM HEPES–KOH, pH 7.9,
1.5mM MgCl2, complete EDTA-free protease inhibitors
and phosphatase inhibitors (Roche, Basel, Switzerland),
10mM KCl, 0.5mM DTT] on ice and centrifugation at
4000g for 10min. Nuclei were lysed by incubation for
20min on ice in buffer C [20 mM HEPES/KOH (pH
7.9), 1.5mm MgCl2, 0.2mm EDTA, 450mM NaCl,
complete EDTA-free protease inhibitors]. Nuclei were dis-
rupted by using a syringe with a 23 gauge needle. Cells
were drawn from the sample tube into the syringe and the
contents were ejected back into the sample tube for ﬁve
times. Extracts were centrifuged at 20000g at 4 Ct o
remove debris. After that, NaCl concentration was
adjusted to 150mM by dilution with buffer C (without
NaCl). Protein concentration in the nuclear extract was
determined by the Bradford assay (Thermo Fisher
Scientiﬁc). Sonicated salmon sperm DNA was added at
a ﬁnal concentration of 100mg/ml and incubated at
room temperature for 15min. After that, extracts were
aliquoted in 1.5ml Eppendorf tubes (extract with 1mg
protein per tube). One microgram of biotinylated DNA
probe was added to the aliquots and extracts were
incubated for 30min at room temperature. Afterwards,
50ml of magnetic streptavidin bead suspension (Miltenyi,
Bergisch Gladbach, Germany) were added and the mixture
was incubated for additional 5min. Proteins binding to
the probes were isolated using themMACS Streptavidin
Kit (Miltenyi). Washing was performed six times with
200ml buffer C supplemented with 150mM NaCl. For
the detection of MMB complex proteins, the washing buf-
fer was supplemented with 0.5% NP40. Proteins were
eluted in two steps with 20ml and 60ml elution buffer at
95 C. Twenty microliters of the eluates and 15mg nuclear
extract (input) were subjected to sodium dodecyl sulfate–
olyacrylamide gel electrophoresis (SDS–PAGE) and west-
ern blot.
SDS–PAGE and western blot
SDS–PAGE and western blot were performed following
standard protocols (23). For detection of DREAM
complex components, the following antibodies were
applied: E2F4 (C-20, Santa Cruz Biotechnology, Santa
Cruz, CA, USA, 1:1000 dilution), Tfdp1 (Ab6, Thermo
Scientiﬁc, 1:400 dilution), p130 (C-20, Santa Cruz
Biotech., 1:1000 dilution), p107 (C-18, Santa Cruz
Biotech., 1:1000 dilution), Lin9, Lin37, Lin52, Lin54
(1:1000 dilution) (19) and Rbbp4 (ab79416, Abcam,
Cambridge, UK, 1:5000 dilution). Nfya was detected
with NF-YA (G-2) monoclonal antibody (Santa Cruz
Biotech., 1:1000 dilution). The BMyb LX015.1 monoclo-
nal antibody was a kind gift from Roger Watson (24).
SILAC
For SILAC analysis, NIH3T3 cells were grown in ‘heavy’
or ‘light’ medium as described above. Nuclear extracts of
density-arrested cells were prepared and DNA afﬁnity
puriﬁcation with the wild-type mouse cyclin B2 probe
and the CDE/CHR mutant probe was performed as de-
scribed above. Four milligrams of nuclear extract were
subjected to afﬁnity puriﬁcation with magnetic strept-
avidin beads (Miltenyi). Columns were washed 10 times
with 200ml buffer C. Equal volumes of eluates from afﬁn-
ity puriﬁcations with wild-type and mutant probe were
combined and separated on a 12% SDS–PAGE. After
separation, the gel was stained with Coomassie Imperial
Protein Stain (Thermo Fisher Scientiﬁc) and 2mm slices
were excised.
Mass spectrometry and data analysis
Tryptic digest of proteins and nanoLC-MS/MS experi-
ments were done as described previously (25). In brief,
tryptic peptides were separated by a reversed-phase
Table 1. Mutations introduced in the CDE and CHR elements of human and mouse cyclin B2 promoters
Promoter  127 CDE CHR  97
Mouse Ccnb2 wild-type 50-GCGTCAGCGGCGCGGTATTTGAATCGCGGAC-30
Mouse Ccnb2 CDEmut 50-GCGTCAGCATTACGGTATTTGAATCGCGGAC-30
Mouse Ccnb2 CHRmut 50-GCGTCAGCGGCGCGGTATGCATATCGCGGAC-30
Mouse Ccnb2 CDE/CHRmut 50-GCGTCAGCATTACGGTATGCATATCGCGGAC-30
Promoter  169 ‘CDE’ CHR  139
Human CCNB2 wild-type 50-GCGCAAGCGACGCGGTATTTGAATCCTGGAA-30
Human CCNB2 ‘CDE’mut 50-GCGCAAGCATTACGGTATTTGAATCCTGGAA-30
Human CCNB2 CHRmut 50-GCGCAAGCGACGCGGTATGCATATCCTGGAA-30
Human CCNB2 ‘CDE’/CHRmut 50-GCGCAAGCATTACGGTATGCATATCCTGGAA-30
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nanoﬂow LC, Axel Semrau GmbH, Sprockho ¨ vel,
Germany) connected to an LTQ-Orbitrap XL mass spec-
trometer (Thermo Scientiﬁc). Mass spectra were acquired
in a data-dependent mode with one MS survey scan (with
a resolution of 60000) in the Orbitrap and MS/MS scans
of the ﬁve most intense precursor ions in the LTQ. The
MS survey range was m/z 350–1500. The dynamic exclu-
sion time (for precursor ions) was set to 120s and auto-
matic gain control was set to 3 10
6 and 20000 for
Orbitrap-MS and LTQ-MS/MS scans, respectively.
Identiﬁcation and quantiﬁcation of proteins were
carried out with version 1.0.12.31 of the MaxQuant
software package (26). Generated peak lists (msm ﬁles)
were submitted to a MASCOT search engine (version
2.2, Matrix Science Ltd, London, UK) and searched
against an IPI mouse protein database (version 3.52).
The mass tolerance of precursor and sequence ions was
set to 7ppm and 0.35 Da, respectively. Methionine oxida-
tion and the acrylamide modiﬁcation of cysteine were used
as variable modiﬁcations. False discovery rates were <1%
based on matches to reversed sequences in the
concatenated target-decoy database. Proteins were con-
sidered if at least two sequenced peptides were quantiﬁed.
Transfections and luciferase assays
For measuring cell cycle-dependent promoter activity with
luciferase reporter assays, NIH3T3 cells were plated in
12-well plates (23000 cells per well). After 24h, cells
were transfected with pGL4 reporter constructs [transfec-
tion mixture per well: 0.2mg promoter reporter plasmid
(pGL4.10), 0.05mg Renilla luciferase plasmid (pGL4.70),
1.5ml GeneJuice (Merck, Darmstadt, Germany), 60ml
DMEM without FCS]. Twenty-four hours after transfec-
tion, cells were starved for 60h by exchanging growth
medium with 10% FCS to DMEM with 0% FCS. Cells
were restimulated for cell cycle re-entry with 20% FCS in
DMEM and collected at given time points by adding
200ml luciferase lysis buffer (Promega). Cells were stored
at  80C and luciferase activity was measured with the
Dual-Luciferase Reporter Assay system (Promega) fol-
lowing the manufacturer’s recommendations. Relative
light units (RLUs) were calculated by normalizing ﬁreﬂy
luciferase activity to Renilla luciferase activity.
Subsequently, RLUs for promoter reporters for each
time point were divided by the RLUs from pGL4.10
empty vector transfections to compensate for changes in
the luciferase expression caused by factors binding to
cryptic sites in the vector backbone, thereby changing
the expression of ﬁreﬂy luciferase reporter independently
from the promoter.
F9 cells (40000 per well in 24-well plates) were trans-
fected with 1ml Fugene HD (Roche, Basel, Switzerland),
0.2mg promoter reporter plasmid (pGL4.10) and 0.02mg
Renilla luciferase plasmid (pGL4.70). For B-myb
knockdown experiments, NIH3T3 cells (12000 per well
in 24-well plates) were transfected with 1ml Fugene HD
(Roche), 0.1mg promoter reporter plasmid (pGL4.10),
0.2mg pSuper construct and 0.02mg Renilla luciferase
plasmid (pGL4.70). Cells were collected 48h after
transfection.
FACS analysis
Cells were ﬁxed overnight at 4 C in one volume PBS/
1mM EDTA and three volumes of absolute ethanol.
DNA was stained with Hoechst 33343 (Invitrogen) at a
ﬁnal concentration of 10mg/ml for 15min at 37 C. DNA
content per cell was measured by ﬂow cytometry on a LSR
II instrument (Becton Dickinson, Franklin Lakes, NJ,
USA). Data analysis was done with BD FACSDiva 6.1
and WinMDI 2.9 software.
Chromatin immunoprecipitations
Density-arrested NIH3T3 cells were ﬁxed in 1% formal-
dehyde for 10min. ChIPs were performed as described
earlier (16,17,27). The following antibodies were used to
precipitate DREAM complex components: E2F4 (C-20,
Santa Cruz Biotech.), p130 (C-20, Santa Cruz Biotech.)
and Lin9 (19). A non-related rabbit antibody was used
as a control for non-speciﬁc signals. For all precipitations,
1mg of antibody and 25ml of Protein G Dynabead suspen-
sion (Invitrogen) were used. qPCR was carried out with
the QuantiTect SYBR Green PCR kit (QIAGEN, Hilden,
Germany). All PCR results were normalized to input
controls. ChIP primer sequences can be obtained upon
request.
Bioinformatic identiﬁcation of CHR elements
The 817 genomic regions in human reference genome
build hg17 (http://genome.ucsc.edu) that were bound by
LIN9, p130 and E2F4 in G0 phase were searched for all
annotated transcription start sites whose [ 200,+200] bp
promoter windows were completely contained within the
regions. We found promoters associated with a total of
792 unique HGNC ofﬁcial gene symbols. A corresponding
set of 792 genes was chosen at random out of the set of all
genes annotated in build hg17. All further analysis was
carried out on all promoters contained in the DREAM-
binding set as well as all [ 200, +200] promoters in the
entire genome associated with the randomized gene set.
MATCH was used to ﬁnd all experimentally validated
CHR motifs (TTTGAA, TTTAAA, TAGGAA and CT
TGAA) in the promoters (28). The PhastCons
17-vertebrate conservation score (29) was then used to
ﬁlter the sites with a posterior probability cutoff of 95%
for at least ﬁve bases and a minimum score of 85% for the
sixth. A gene was counted as a ‘CHR-containing gene’ if it
had at least one conserved CHR site in any of its asso-
ciated promoter windows. Signiﬁcance of the overlap
between DREAM-binding promoters and CHR-
containing genes was computed using Fisher’s exact test.
RESULTS
Components of the DREAM complex bind to the
CDE/CHR sites of the mouse cyclin B2 promoter
In an earlier report, we had shown that the CDE/CHR
element in the mouse cyclin B2 gene is essential for
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intended to identify the proteins binding to these sites in
G0. To this end, we applied a mass spectrometry-based
approach employing the method of stable isotope labeling
with amino acids in cell culture (SILAC). After density
arrest in G0, DNA afﬁnity puriﬁcation was performed
with mouse NIH3T3 nuclear cell extracts using bio-
tinylated DNA probes for the wild-type promoter when
cells grown in ‘heavy’ medium and a CDE/CHR double-
mutant promoter probe for extracts from cells grown in
‘light’ medium (Table 1). Eluates with DNA-binding
complexes were mixed, the sample resolved by SDS–
PAGE and the resulting lane cut into equal segments that
were then subjected to trypsin digestion. Subsequently,
tandem MS/MS analysis was performed for identiﬁcation
and relative quantiﬁcation of proteins which bind to the
wild-type probe compared with the CDE/CHR-mutant
promoter (Figure 1). A high ratio of signals for
13C
versus
12C and
15N versus
14N containing tryptic peptides
indicated proteins to bind to the cyclin B2 promoter in G0
requiring the intact CDE and CHR elements.
Nine proteins were enriched more than 4-fold at the
wild-type promoter when compared with the mutant probe
(Supplementary Table S1). Interestingly, seven of these
nine proteins are members of the DREAM complex
which is known to be involved in the regulation of several
cell cycle-regulated genes. In G0, the mammalian
DREAM complex consists of E2F4, DP1, p130/p107
and the MuvB core proteins LIN9, LIN37, LIN52,
LIN54 and RBBP4 (19). Six out of that group of proteins
were observed to be enriched at the wild-type probe more
than 7-fold (Table 2). Rbbp4 was found to bind to both
the wild-type and the mutant probe. Interestingly, Rbbp4
enrichment at the wild-type promoter was only  2-fold
and thereby considerably less than the other DREAM
components. Tryptic peptides of Lin52 and Dp1 could
not be detected in the screen (Supplementary Table S2).
Thus, we show that the DREAM complex, that was
shown to repress cell cycle genes in G0/G1 (19), binds to
the CDE/CHR element of the mouse cyclin B2 promoter
in G0.
The CHR is essential for recruiting the DREAM complex
to the cyclin B2 promoter in vitro and in vivo
After applying a DNA probe mutated in both the CDE
and CHR sites for identiﬁcation of DREAM binding to
the mouse cyclin B2 gene, we were wondering if both
elements are required for the DREAM complex to asso-
ciate with the cyclin B2 promoter. Since E2F4 is an essen-
tial component of the complex and the DNA sequence of
the CDE is similar to a canonical E2F-binding site, one
would assume that E2F4 binds to the CDE. However, it
was shown that the human in contrast to the mouse cyclin
B2 promoter does not hold a CDE next to the CHR
(17,18). Therefore, comparing protein binding to the
mouse and human cyclin B2 promoters should yield indi-
vidual contributions of the CDE and the CHR to
DREAM binding.
We performed DNA afﬁnity puriﬁcation with biotinyl-
ated human and mouse wild-type and mutated (CDE, CHR
and CDE/CHR) cyclin B2-promoter probes (Table 1) from
nuclear extracts of density-arrested NIH3T3 cells followed
by western blot analysis. A fragment of the mouse Gapdhs
promoter served as a negative control. Using antibodies
against DREAM proteins, we observed that all complex
components were enriched at both the human and mouse
wild-type cyclin B2 promoters (Figure 2A). Employing
this DNA pull-down western approach, we detected
density-arrested
NIH3T3 cells
density-arrested
NIH3T3 cells
„heavy“
+ 13C-Lys/ 13C,15N-Arg
nuclear extract
DNA-affinity purification of 
proteins binding to the
cyclin B2 wild-type probe
nuclear extract
mix eluates
SDS-PAGE, trypsin digestion
identification and quantification of proteins
by MS/MS
DNA-affinity purification of 
proteins binding to the
cyclin B2 CDE/CHR mutant probe
„light“
+ 12C-Lys/ 12C,14N-Arg
Figure 1. Strategy for the identiﬁcation of proteins binding to the
CDE/CHR tandem element of the mouse cyclin B2 promoter.
NIH3T3 cells were labeled by cultivation in ‘heavy’ medium lacking
natural Lys and Arg amino acids supplemented with
13C6 lysine and
13C6,
15N4 arginine or regular ‘light’ medium (
12C-Lys/
12C,
14N-Arg).
After density arrest in G0, nuclear extracts were prepared. DNA afﬁnity
puriﬁcation was performed with biotinylated cyclin B2 wild-type and
CDE/CHR mutant probes. Precipitated proteins were separated by
SDS–PAGE, digested with trypsin and analyzed by mass spectrometry.
Table 2. Identiﬁcation of components of the DREAM complex
binding to the CDE/CHR element in the mouse cyclin B2 promoter
Protein Unique peptides sequenced Ratio wt/mut
Lin9 5 27.3
p130 9 21.9
Lin37 2 16.4
Lin54 7 12.2
E2f4 6 10.6
p107 4 7.2
After DNA afﬁnity puriﬁcation of proteins from stable isotope-labeled
nuclear extracts, relative protein abundance was measured by mass
spectrometry. Proteins are enriched at the wild-type mouse cyclin B2
promoter in comparison to a promoter harboring a CDE/CHR double
mutation. The enrichment factor of proteins binding to the wild-type
probe is shown as well as the number of unique peptide sequences.
Nucleic Acids Research,2012, Vol.40, No. 4 1565E2f4, p107, p130, Lin9, Lin37, Lin54 and Rbbp4 proteins
that we had previously identiﬁed by mass spectrometry.
Furthermore, DREAM complex components Lin52 and
Dp1, which were not observed in the SILAC experiment,
also bound to the mouse and human cyclin B2 promoters.
Thus, we could identify all known proteins of the mam-
malian DREAM complex bound to the wild-type human
and mouse cyclin B2 promoters.
Given the ability of the DREAM complex to bind to the
mouse and human cyclin B2 probes, we tested the contri-
bution of CDE and CHR sites to DREAM binding relative
to each other and to the wild-type probes. Although the
human cyclin B2 promoter does not contain a functional
CDE as shown by sequence comparisons and mutation
analyses (17,18), the DREAM complex can nevertheless
bind to it. We observed that the DREAM components are
enriched to a higher degree on the mouse cyclin B2 probe
than on the human probe when compared with input
(Figure 2A). To rule out that proteins from mouse cell
extracts preferentially bind to the mouse compared with
the human probe, we looked for binding of DREAM
complex components to human and mouse cyclin B2 pro-
moters in density-arrested human foreskin ﬁbroblasts.
Also human DREAM proteins bound more avidly to
the mouse probe than to the human promoter (data not
shown).
When probes of the mouse cyclin B2 promoter with a
mutated CDE were used, a slight reduction of DREAM
protein binding could be observed. In contrast, binding of
DREAM proteins to the probe ‘CDE’ was essentially the
same as that to the wild-type promoter (Figure 2A). The
probe ‘CDE’ was created on the basis of human cyclin B2
by mutating the nucleotides corresponding to the position
of the CDE in the mouse promoter.
Interestingly, mutation of the CHR in both human and
mouse probes led to a loss of binding of DREAM
complex components to the cyclin B2 promoters.
Double-mutation of both CDE and CHR elements did
not show a further reduction in binding of all proteins
analyzed. Only Rbbp4 was still binding to the probes
with mutated CHR to almost the same degree as to the
wild-type probe, which is in agreement with the data from
the MS/MS analyses (Supplementary Table S2). Binding
of the nuclear transcription factor-Y subunit alpha
(Nfya), that had been shown to bind to CCAAT-boxes
of the cyclin B2 promoter (31), is independent of CDE
or CHR mutations and served here as a positive control
for equal pull-down efﬁciency (Figure 2A). Taken
together, these data demonstrate that the CHR is essential
for binding of the DREAM complex to the cyclin B2 pro-
moters. The CDE in the mouse promoter enhances
binding of the DREAM complex, but is not indispensable
for interaction of the complex with the DNA.
Consistently, after mutation of the CDE in the cyclin B2
promoter slightly reduced protein binding was observed
(Figure 2A).
In addition to the in vitro DREAM binding as assayed
by pull-down western approach, we tested in vivo binding
of the DREAM proteins to the CDE and CHR elements
by chromatin immunoprecipitation (ChIP). To this end,
we stably transfected NIH3T3 cells with luciferase
reporter plasmids containing the mCcnb2-short and
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Figure 2. In vitro analysis of DREAM protein binding to cyclin B2 wild-type or mutant promoters. Nuclear extracts of density-arrested NIH3T3
cells were employed for DNA afﬁnity puriﬁcation using biotinylated human or mouse cyclin B2 promoters. (A) Binding was tested to wild-type,
CDE, CHR or CDE/CHR mutant DNA probes by western blot analysis. As a negative control, a fragment of the Gapdhs promoter was used. As a
protein binding to all cyclin B2 probes containing CCAAT-boxes, Nfya was detected. (B) Binding of the DREAM complex to the cyclin B2
promoters is independent of CCAAT-boxes. A truncated fragment of the mouse cyclin B2 promoter ending upstream of the CDE lacking the
CCAAT-boxes was assayed for DREAM binding in comparison to a probe of the same length but with mutated CDE and CHR elements.
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CHR or CDE/CHR mutants (Table 1). These constructs
contained the same DNA sequences that we had used for
probes in the pull-down assays. Nuclear extracts were col-
lected from cells that were density arrested and ChIPs
were performed for E2f4, p130 and Lin9 binding to the
stably transfected promoters. For all three proteins,
maximal binding appeared at both wild-type promoters
(Figure 3). When the CDE in the mouse cyclin B2
promoter and the corresponding region in the human
promoter were mutated, a slight decrease of E2f4, p130
and Lin9 binding was observed. In contrast, binding of all
proteins to both promoters was reduced to background
level when the CHR was mutated. In vivo binding was
not reduced further with the CDE/CHR double
mutation in the promoters (Figure 3). Interestingly, the
ChIP signals at the mouse wild-type promoter appeared
to be stronger in comparison to the human promoter,
consistent with the higher afﬁnity of DREAM proteins
to the mouse compared with the human promoter in the
pull-down western experiments (Figures 2 and 3).
Therefore, regardless of the experimental approach, the
data strongly suggest that the DREAM complex is
binding to the cyclin B2 promoter primarily via the
CHR. A CDE can support the binding, but is not essential
for the interaction of DREAM proteins with the DNA.
The CHR element participates in transcriptional
activation and repression of cyclin B2 promoters
With the DREAM complex binding to cyclin B2 pro-
moters mostly through the CHR, we wished to have a
more precise look at the function of this site in regulating
promoter activity. In two earlier reports, we had identiﬁed
the CHR as the dominant element for cell cycle-dependent
repression in cyclin B2 promoters (17,30). However, we
did not search for a contribution to transcriptional acti-
vation. Additionally, in experiments published earlier, the
promoter constructs increased activity later in the cell
cycle even when the CHR was mutated (17,30). As an
important technical note, we found that pGL3 luciferase
reporter vectors were responsible for a good part of the
regulation that could not be attributed to a particular
promoter element. Another change to earlier experiments
was that we have employed the hCCNB2-short and
mCcnb2-short fragments for DNA afﬁnity puriﬁcation
and ChIP experiments. These promoter fragments were
much shorter than the segments employed for the original
cyclin B2 reporter assays (17,30). Since CCAAT-boxes
and CDE/CHR elements are present in the short con-
structs, we assumed that these promoter fragments are
able to mediate cell cycle-dependent regulation in the
same manner as the long variants. However, experimental
validation of this assumption was still necessary. To
address these questions, we cloned both the long and
short fragments of the mouse and human promoters into
pGL4 series plasmids, which are largely devoid of cryptic
transcription factor binding sites that were masking the
real promoter activity in their predecessors. All four
wild-type and mutant promoter–reporter constructs were
assayed in serum-starved cells following their activity after
serum stimulation throughout the subsequent cell cycle
(Figure 4).
Expression from wild-type human and mouse cyclin B2
promoters was found at background level in G0 cells
(Figure 4). Transcription was activated at the beginning
of S phase at around 15h after serum restimulation.
Expression of the reporters reached a maximum after
27h in G2/M. Importantly, the expression patterns from
wild-type promoters reﬂect cyclin B2 mRNA expression
from endogenous genes (Supplementary Figure S1).
Regulation during the cell cycle of long and short
promoter constructs was nearly identical, indicating that
short cyclin B2 promoter fragments including merely CCA
AT-boxes and CDE/CHR elements are sufﬁcient for cell
cycle-dependent expression. Cell cycle-dependent activity
of the short wild-type mouse cyclin B2 promoter activity
increased 30-fold when expression of the peak in G2/M
was compared with G0. The increase in activity between
G0 and G2/M phase was found to be higher in the mouse
(mCcnb2 short, 30-fold; mCcnb2 long, 42-fold) than in the
human promoters (hCCNB2 short, 12-fold; hCCNB2
long, 13-fold).
We compared the activity of the cyclin B2 promoters
with mutations in the CDE, CHR or both elements.
Mutation of the CDE sites in the mouse cyclin B2
promoter constructs resulted in a loss of repression of
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Figure 3. Chromatin immunoprecipitation analysis of DREAM proteins binding to (A) mouse or (B) human cyclin B2 promoters in vivo. NIH3T3
cells were stably transfected with wild-type, CDE, CHR or CDE/CHR mutant promoter constructs. Nuclear extracts of density-arrested cells were
prepared and ChIPs were performed with antibodies targeting E2f4, p130 and Lin9. As a negative control, a non-targeting rabbit antibody was used.
All signals are given relative to the input.
Nucleic Acids Research,2012, Vol.40, No. 4 1567 2-fold for Ccnb2 long and 3-fold for Ccnb2 short in G0
and early G1 phase. In contrast, mutation of the corres-
ponding ‘CDE’ region in the human promoter constructs
essentially did not alter the activity of the promoters in the
early cell cycle phases. These differences in the role of the
CDE region in mouse and human cyclin B2 promoters are
consistent with published observations (17,30). Mutation
of the CDE regions in all four promoters did not change
timing of increase in activity beginning at 15h. In
contrast, the reporters with CHR mutations or CDE/
CHR double mutations lost cell cycle-dependent
regulation (Figure 4). Higher activities were observed in
G0 and G1. Furthermore, promoter activity of the CHR
and double mutants ﬂuctuated <2-fold during all phases
of the cell cycle. Interestingly, no substantial increase of
promoter activity occurred in S, G2 or M phases beyond
the activity already reached in G0, leaving the activity of
CHR mutant promoters in G2/M consistently below the
maximum activity reached for the corresponding wild-
type constructs. Interestingly, this suggests that about a
3-fold activation is contributed by CHR elements and the
factors binding to them. Taken together, the luciferase
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Figure 4. Reporter activities of human and mouse cyclin B2 wild-type and mutant promoters. NIH3T3 cells were transfected with the wild-type (wt)
and mutant (CDE, CHR, CDE/CHR) promoter-luciferase reporter constructs (A) mouse Ccnb2 long, (B) mouse Ccnb2 short, (C) human CCNB2
long and (D) human CCNB2 short. Cells were arrested in G0 by serum starvation and stimulated to re-enter the cell cycle by addition of FCS to the
media. Cells were collected every 3h and luciferase activity was measured. (E) To determine cell cycle distribution of cell populations at the different
time points, the DNA in the cells was stained with Hoechst 33342 and ﬂuorescence was measured by ﬂow cytometry.
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necessary for repression as well as activation of human
and mouse cyclin B2 promoters, whereas the CDE in the
mouse gene is only of minor importance for repression
and the human promoter does not contain a functional
CDE.
Sequence and position of CHR and CCAAT-box elements
in cyclin B2 promoters are phylogenetically well conserved
We observed that the minimal cyclin B2 promoter with
lengths of 210bp (mouse) or 263bp (human) gave the
same regulation as much longer promoter fragments
(Figure 4) similar to the mRNA expression from the en-
dogenous cyclin B2 gene (Supplementary Figure S1).
Thus, the minimal promoter should hold all relevant tran-
scription factor-binding sites. We compared nucleotide se-
quences of cyclin B2 genes from 26 mammalian species
just upstream from their translational start sites using
the UCSC Genome Browser (32). Only four elements
were identiﬁed as perfectly conserved in their nucleotide
sequence in all cyclin B2 promoters compared: the three C
CAAT-boxes and the CHR. Interestingly, the sequence
of the mouse CDE was not observed in many of the
other mammalian genes (Supplementary Figure S2). This
lack of phylogenetical conservation of the CDE and the
non-existence of canonical E2F-sites support the conclu-
sion that cell cycle-dependent regulation and binding
of the DREAM complex can occur exclusively through
a CHR.
The CCAAT-boxes had already been shown to be ne-
cessary for basal activity of the promoter (17,31,33). Also
the distance of  33bp between two neighboring CCAAT
-boxes and the distance of the CCAAT-boxes to the CHR
is highly conserved (Supplementary Figure S2). In
addition, no other highly conserved elements could be
identiﬁed upstream of the 200bp minimal promoter in a
region of 800nt upstream of the translational start site. In
general, the data suggest that transcription of cyclin B2 is
mainly controlled by three CCAAT-boxes and the CHR.
CCAAT-boxes are not required for binding of the
DREAM complex to the CHR
Three CCAAT-boxes and the CCAAT-binding factors
Nfya, Nfyb and Nfyc have been implicated in the regula-
tion of the cyclin B2 promoter before (17,31). In addition,
CCAAT-boxes are the only well-conserved elements be-
sides the CHR. Therefore, we tested if CCAAT-boxes
are necessary for binding of DREAM. To address this
question, we created biotinylated probes of the mouse
cyclin B2 promoter with a length of 130nt ending just
upstream of the CDE element. These probes included the
CDE/CHR element but not the CCAAT-boxes (Ccnb2–C
CAAT, Supplementary Figure S2). Furthermore, we
ampliﬁed another probe of the same length, but with
mutated CDE and CHR elements. Using these probes
for pull-down western experiments with nuclear extracts
of density-arrested NIH3T3 cells, we were able to compare
protein binding to probes with or without CCAAT-boxes.
Binding of Nfya is lost in the probe lacking CCAAT
-boxes. However, all the analyzed DREAM proteins are
still bound to the mouse cyclin B2 promoter even in the
absence of CCAAT-boxes (Figure 2B). This experiment
indicates that there is no direct cooperation between the
CHR element and the CCAAT-boxes in recruiting the
DREAM complex. The CHR is the only phylogenetically
well-conserved element that is essential for binding of
DREAM.
The CHR in the cyclin B2 promoter is required for
binding of the B-myb-containing MMB complex
It was shown earlier that the composition of the DREAM
complex changes during the cell cycle. In early cell cycle
phases, the complex includes E2F4/DP1 together with
p130/p107. This complex seems to have repressing func-
tions. Later in the cell cycle, a shift in composition from
E2F4/DP1 and p130/p107 to B-MYB is observed.
Together with the MuvB core proteins, B-MYB forms
the MMB (MYB-MuvB) complex that participates in
the activation of various genes (19–21,34,35). B-MYB is
essential for activation of many genes expressed in S, G2
and M phases (10,22,35). Since we were able to show that
the CHR participates in repression as well as in activation
of cyclin B2, we were wondering if MMB can bind to the
CHR. We performed pull-down assays applying the same
probes as used for the puriﬁcation of the repressing
DREAM complex. However, we employed extracts from
proliferating NIH3T3 cells instead of density-arrested
cells since B-myb is not expressed (36,37) and the MMB
complex cannot be detected in G0 cells (19). Western-blot
analyses showed that B-myb binds to mouse and human
cyclin B2 promoters with similar afﬁnity (Figure 5A).
Mutation of the CHR leads to a loss of B-myb binding
to both promoters. Mutation of the CDE region in both
genes does not affect binding of B-myb. Apparently,
binding of B-myb to cyclin B2 promoters is independent
of CDE sites, but dependent on CHR elements. Since in a
lysate from proliferating cells both the DREAM and
MMB complexes are present, it is not possible to discrim-
inate if detected proteins of the MuvB core are part of
DREAM or MMB. To overcome this problem, we
employed F9 embryonal carcinoma cells derived from a
mouse testicular teratocarcinoma. F9 cells were shown not
to form the DREAM complex in any cell cycle phase, but
to carry the MMB complex (34). Thus, in these cells
DREAM-dependent repression of promoters through
CHR elements should not be possible. We then performed
DNA afﬁnity puriﬁcation with nuclear extracts of F9 cells
to ﬁnd out if B-myb binds to the cyclin B2 promoters
together with other components of the MMB complex.
Indeed, proteins of the MuvB core bind to the wild-type
cyclin B2 probes as well as to the probes with mutated
CDE (Figure 5B). Consistent with the notion that F9
cells lack DREAM, E2f4 and p130 were clearly detectable
in the nuclear extracts, but did not bind to any of the
DNA probes which again proves that DREAM does not
form in F9 cells and that protein binding to the DNA
probes in our assay is highly speciﬁc. To evaluate if
binding of MMB to the CHR is indeed necessary for the
maximal activity of the cyclin B2 promoters, we trans-
fected NIH3T3 cells with wild-type cyclin B2 luciferase
Nucleic Acids Research,2012, Vol.40, No. 4 1569reporters or constructs with mutated CHR elements
together with two different plasmids expressing shRNAs
targeting B-myb. The activity of the wild-type cyclin B2
promoters is clearly reduced when B-myb is knocked down
relative to a control that was cotransfected with a non-
targeting GFP-shRNA construct. This effect was comple-
tely abolished when the CHR was mutated (Figure 5C).
Taken together, these experiments demonstrate that the
B
C
A
0
20
40
60
80
100
120
sh-GFP
sh-Bmyb1
sh-Bmyb 2
sh-GFP
sh-Bmyb 1
sh-Bmyb 2
sh-GFP
sh-Bmyb1
sh-Bmyb 2
sh-GFP
sh-Bmyb 1
sh-Bmyb2
R
L
U
 
[
%
]
t w t wR H C R H C
mouse Ccnb2 short human CCNB2 short
mouse cyclin B2
B-myb
input wt CDE    CHR    CDE/   negative
control CHR
input wt “CDE” CHR  “CDE”/
CHR
human cyclin B2
Nfya
mouse cyclin B2 human cyclin B2
B-myb
Lin9
Lin37
Lin54
E2f4
p130
Nfya
input wt CDE 
control
wt “CDE” CHR “CDE”/
CHR
CHR CDE/
CHR
 
Figure 5. The MMB complex binds and activates the cyclin B2 promoters through the CHR. (A) Nuclear extracts of proliferating NIH3T3 cells were
employed for DNA afﬁnity puriﬁcation with biotinylated DNA probes of the human and mouse cyclin B2 promoters. Protein binding to wild-type,
CDE, CHR or CDE/CHR mutant promoter fragments was tested by western blot analysis. As a protein binding to all cyclin B2 probes containing
CCAAT-boxes, Nfya was detected. As a negative control, a fragment of the Gapdhs promoter was used. (B) Binding of the MMB complex to the
mouse and human cyclin B2 DNA probes was assayed with DNA afﬁnity puriﬁcation of proteins derived from F9 cell nuclear extracts followed by
western blot. Note that the DREAM complex components E2f4 and p130 do not bind to the probes. (C) To determine the effect of B-myb
knockdown on the activity of mouse and human cyclin B2 promoters, NIH3T3 cells were transfected with the reporter constructs mouse Ccnb2
short and human CCNB2 short (wild-type or CHR mutant) together with vectors expressing shRNAs targeting B-myb (sh-Bmyb 1, sh-Bmyb 2). A
shRNA construct expressing a non-targeting GFP-shRNA served as a negative control (sh-GFP). Luciferase activities were measured 48h after
transfection.
1570 Nucleic Acids Research, 2012,Vol.40, No. 4MMB complex binds to the CHR independently of a
CDE and that this interaction is necessary for full acti-
vation of the cyclin B2 promoter.
Promoters binding the DREAM complex often contain
CHR elements that are conserved in vertebrate genomes
The data on cyclin B2 regulation suggest a central role for
the CHR element in cell cycle-dependent transcription. To
date, roughly a dozen promoters have been experimentally
validated to be regulated through CHRs or CDE/CHR
tandem sites (4). We wondered if DREAM binding to
CHR promoters is limited to the cyclin B2 gene or if it
is observed in a larger number of promoters. The most
commonly reported CHR corresponds to the consensus
TTTGAA. Another functional CHR with the sequence
TTTAAA was identiﬁed in the cyclin B1 promoter. The
mouse B-myb promoter possesses a CHR with the
sequence TAGGAA and the human cyclin A2 gene
contains a functional CHR with the sequence CTTGAA
[reviewed in (4)]. Using these four veriﬁed CHR sites as a
basis, we searched promoters described to bind DREAM
components. To this end, we employed a dataset of DNA
fragments that were shown by ChIP-chip assays to bind
DREAM proteins in resting cells (19). The dataset
comprised 817 DNA fragments observed to bind E2F4,
p130 and LIN9 in G0. We searched these ChIP-chip frag-
ments for transcription start sites identifying promoters of
792 genes annotated in the HGNC database. We searched
for subgroups of these promoters, which possess evolu-
tionary conserved CHR sites located in a region of
200bp upstream or downstream from transcriptional
start sites in the human genome. To qualify as a conserved
CHR, a site had to have a >95% conservation score for
ﬁve out of six nucleotides and the sixth score had to be
>85% when the human sequence was compared with 16
other vertebrate genomes. We identiﬁed 149 genes
matching all requirements (Supplementary Table S2)
which accounts for 18.8% of all DREAM-binding pro-
moters (Figure 6A). Interestingly, 76% of the identiﬁed
genes contain conserved CHR elements with the
sequence TTTGAA (or inverse TTCAAA). A similar per-
centage of all experimentally validated CHRs have the
same nucleotide sequence (4). This indicates that the
CHRs with the sequence TTTGAA are likely the most
common sites among the four used for the search.
As a negative control, we screened a set of randomly
selected genes for CHRs following the same protocol.
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Figure 6. In silico identiﬁcation of CHR elements in promoters of genes bound by components of the DREAM complex. (A) The 792 promoters
have been identiﬁed to bind the DREAM complex in ChIP-Seq assays (19). 149 of these genes (18.8%) possess CHR elements that are located in a
distance of 200bp relative to the transcription start site and that are phylogenetically conserved in vertebrates. As a control, a set of 792 randomly
selected genes was assayed using the same parameters. In this control group, 60 conserved CHR elements were identiﬁed (7.6%). Using the Fisher’s
exact test, the overlap between DREAM-binding genes and CHR-containing genes appears to be highly signiﬁcant (P=4.8 10
 11). (B) Randomly
selected genes from subgroups of identiﬁed genes were further tested by chromatin immunoprecipitation. Nuclear extracts from density-arrested
NIH3T3 cells were prepared and ChIPs were performed with antibodies targeting E2f4, p130 and Lin9. As a negative control, a non-targeting rabbit
antibody was used (IgG). All signals are given relative to the input.
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CHR elements (Figure 6A). Using the Fisher’s exact test,
the overlap between DREAM-binding genes and
CHR-containing genes appears to be highly signiﬁcant
(P=4.8 10
 11). To further substantiate these ﬁndings,
we performed ChIP analyses with antibodies targeting
E2f4, p130 and Lin9 using extracts from density-arrested
NIH3T3 cells. We randomly selected genes from the fol-
lowing subgroups: (i) genes that bind DREAM and were
identiﬁed to possess conserved CHR elements (DREAM
positive, CHR positive); (ii) genes from the control group
that have not been identiﬁed to bind DREAM and which
do not contain CHRs (DREAM negative, CHR negative);
and (iii) genes from the control group that have not been
identiﬁed to bind DREAM but possess evolutionary
conserved CHR elements (DREAM negative, CHR
positive). For the genes with CHR elements, we designed
primers for the ampliﬁcation of DNA fragments that com-
pletely overlap with the CHR regions. A possible binding
of DREAM components to CHR-negative promoters was
tested with primers for the ampliﬁcation of fragments that
overlap with the transcription start. As predicted, we show
binding of E2f4, p130 and Lin9 to all selected promoters
from the subgroup of DREAM-positive and CHR-
positive genes and no binding of these proteins to the
genes of the control group lacking a CHR element
(Figure 6B). One even more fascinating question was
whether one would detect DREAM proteins at the pro-
moters that have not been identiﬁed in the original screen
to bind DREAM, but possess conserved CHRs. In fact,
while 8 out of the 12 randomly selected genes were negative
for binding of DREAM components, one (Rtkn2) was
clearly positive for E2f4, p130 and Lin9 binding.
Furthermore, a weak but detectable binding of these
DREAM proteins to other three genes (Sephs1, Reep4,
Dzip1) could be shown as well (Figure 6B). Therefore,
the number of promoters that bind DREAM proteins
and that possess evolutionary conserved CHR elements
will be even higher than the 149 genes we have identiﬁed
in our screen with the employed parameters.
Taken together, these observations suggest that the
CHR is a highly conserved element in many promoters
that are regulated by the DREAM complex.
An inverse CHR in the Ube2c promoter mediates cell
cycle-dependent transcription and binding of the DREAM
and MMB complexes
One of the genes that were identiﬁed in the screen of
DREAM-binding promoters to contain a CHR element
is the ubiquitin-conjugating enzyme Ube2c gene
(Supplementary Table S2). Ube2c is an important regula-
tor of the cell cycle. It is required for the destruction of
mitotic cyclins and for exit from mitosis (38,39). Like
cyclin B2, expression of Ube2c is regulated on the tran-
scriptional level with a maximal expression in G2/M
(Supplementary Figure S1) (40,41). The sequence of the
CHR in the Ube2c promoter follows the consensus TTTG
AA. However, this element differs from previously tested
CHRs in that its orientation is inverse (Figure 7A). To
ﬁnd out if such CHR elements predicted by the
bioinformatic screen are also functional in cell
cycle-dependent regulation and DREAM/MMB binding,
we tested a fragment of the mouse Ube2c promoter (nu-
cleotides  478 to  3 relative to the translation start) for
transcriptional regulation in reporter assays. In
serum-starved NIH3T3 cells, activity of the promoter is
low and starts to increase at 12h after serum restimulation
reaching maximal expression 24h after restimulation
(45-fold activation) (Figure 7B). The activity of a con-
struct with a mutated CHR is 19-fold higher than the
wild-type reporter in the serum-starved cells (0h time
point) indicating a strong loss of repression for the
mutant. However, in contrast to the cyclin B2 constructs
with mutated CHRs that do not show any cell
cycle-dependent regulation, the Ube2c CHR mutant is
still activated  7-fold in a cell cycle-dependent manner.
This change in activity could be caused by other activating
transcription factors regulating the Ube2c promoter inde-
pendently of the CHR. In contrast to the cyclin B2
promoter, several highly conserved regions in addition
to the CHR may serve as potential binding sites for add-
itional regulators (Supplementary Figure S3). We also
searched for potential CDE sites close to the CHR.
Upstream of the CHR, the nucleotide composition does
not follow the CDE consensus. However, the region
downstream of the CHR consists only of guanines and
cytosines and displays a sequence similar to CDE sites.
Mutation of this G/C-rich region did not alter cell
cycle-dependent transcription (Figure 7B). Thus, the
G/C-rich element cannot be marked as a CDE.
Binding of the DREAM and MMB components to the
promoter fragment was shown by DNA afﬁnity puriﬁca-
tion followed by western blot (Figure 7C and D).
Matching with the functional data employing the cyclin
B promoter, binding of DREAM and MMB proteins is
disrupted when the CHR is mutated. Mutation of the
G/C-rich downstream region does not affect binding of
the DREAM and MMB complexes. Knockdown of
B-myb leads to a 2-fold reduction of the Ube2c
wild-type promoter activity and to minor changes in the
activity of the CHR mutant (Figure 7E).
Taken together, these experiments constitute veriﬁca-
tion for the ability to identify functional CHR elements
by a bioinformatic approach. Furthermore, we provide
evidence that inverse CHR elements are functional and
can bind the DREAM and MMB complexes.
DISCUSSION
Transcriptional regulation of genes that are differentially
expressed during the cell cycle is a central mechanism of
cell cycle control. The observation that some genes whose
transcription is repressed in G0 and G1 but is activated in
S, G2 and M phases are controlled by CDE and CHR
elements was made more than a decade ago (5–7).
However, protein binding to the elements and the
general mechanism of CDE/CHR-dependent transcrip-
tional regulation still remain to be elucidated.
Here, we provide evidence that protein complexes
named DREAM and MMB bind to the promoter of
1572 Nucleic Acids Research, 2012,Vol.40, No. 4human and mouse cyclin B2 genes as well as to the mouse
Ube2c promoter. We ﬁnd that DREAM is the long
sought-after complex binding to the CHR in resting cells.
E2F- and pRB-related proteins had been described
as components of a complex that was ﬁrst identiﬁed in
Drosophila and named dREAM (Drosophila RBF,
dE2F2 and dMyb-interacting proteins) (42). Later, the
ortholog complex, containing E2F4, DP1, p130 and
p107 as essential components, has been identiﬁed as the
mammalian DREAM complex. In addition to these pro-
teins, this complex consists of RBBP4 and the MuvB-like
LIN proteins LIN9, LIN37, LIN52 and LIN54 that form
the MuvB-core of DREAM (19,20). By ChIP, components
of human DREAM were shown to bind to many pro-
moters of genes that are differentially expressed during
the cell cycle (19,20). The DREAM complex binds to
these promoters in G0 and early G1 and is necessary for
repression of transcription. When a cell progresses
through the cell cycle, E2F4/DP1 and p107/p130 appear
to be released from the DREAM complex, which then
incorporates B-MYB. As this complex consists of the
MuvB-core and B-MYB, it is designated as the MMB
(MYB-MuvB) complex that activates gene expression in
S phase (19–21,34,35,43).
Here, we show that DREAM binding to cyclin B2 pro-
moters in G0 is dependent on an intact CHR since
mutation of this element results in a loss of DREAM as-
sociation in vitro and in vivo. Interestingly, six of the nine
nuclear proteins identiﬁed by mass spectrometry to be
enriched >4-fold at the wild-type probe are components
of DREAM. Of the remaining three proteins, Snd1,
Cand1 and Cﬂ1, only Snd1 is a factor that has been impli-
cated in transcriptional regulation (44–47). However, in
pull-down western experiments we were unable to corrob-
orate the observation that Snd1 binds to the CDE or CHR
sites of the cyclin B2 promoter. Therefore, it seems likely
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Figure 7. Conﬁrmation of a functional CHR element binding DREAM and MMB in the mouse Ube2c promoter predicted through bioinformatic
analyses. (A) The inverse CHR is located close to the transcription start and in proximity to two inverse CCAAT-boxes. The region downstream of
the CHR is rich in guanines and cytosines (blue, G/C-rich). (B) Activities of the wild-type Ube2c promoter, a CHR mutant and a promoter with
mutated G/C-rich region were tested in luciferase reporter assays in serum-starved and restimulated NIH3T3. (C) Binding of the DREAM complex
to Ube2c probes was assayed with DNA afﬁnity puriﬁcations using nuclear extracts of density-arrested NIH3T3 cells followed by western blot. (D)
The analogous experiment with nuclear extracts from proliferating F9 cells was performed to test binding of the MMB complex to the Ube2c
promoter. (E) The effect of B-myb knockdown on Ube2c promoter reporter constructs was tested with luciferase assays in proliferating NIH3T3
cells. All experiments were essentially performed as shown for cyclin B2 (Figures 2, 4 and 5).
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CHR of the cyclin B2 promoter in G0.
Interestingly, while mutation of the CDE/CHR tandem
element resulted in dissociation of E2F4, p107, p130, Lin9,
Lin37 and Lin54 from the cyclin B2 promoter (factors for
differential binding from 7.2 to 27.3), the amount of
bound Rbbp4 changed only to a small degree (factor
1.9) (Supplementary Table S1). A possible explanation
for the lack of stoichiometric loss of binding is that
Rbbp4 is not only part of the DREAM complex, but
can also bind directly to histones (48) or is additionally
a component of other chromatin remodeling complexes
like the NuRD and Sin3 complexes (49,50). These
complexes are able to bind either to transcription factors
contacting the DNA or directly to methylated DNA.
Many proteins that are part of both complexes like
Mta1, Mta2, Mbd3, Chd4, Hdac1, Hdac3, Gatad2b,
Sin3a and Sap18 could be identiﬁed by mass spectrometry
to bind to the mouse cyclin B2 promoter (Supplementary
Table S1). Also binding of these complex components to
wild-type versus CDE/CHR mutant cyclin B2 probes only
differed to a small extend. Since the basal cyclin B2
promoter is rich in GC sequences, it is likely that the
NuRD complex including Rbbp4 is able to bind to the
probes independent from the CDE/CHR. It remains
open which function, in addition to its DREAM associ-
ation, binding of Rbbp4 to complexes like NuRD and
Sin3 may have in transcriptional regulation of the cyclin
B2 promoter. Furthermore, it is not known what impact
binding of NuRD and Sin3 complexes to the promoter has
on cyclin B2 expression.
After ﬁnding that DREAM binds the cyclin B2
promoter preferentially through the CHR and not
through the CDE as a potential E2F4-binding site, the
question comes up which protein in this complex directly
contacts the DNA. Recently, LIN54 was shown to bind to
DNA in a sequence-speciﬁc manner (51). Two sites were
proposed for LIN54 binding in the human CDC2
promoter. One of the binding elements overlaps with the
CHR, whereas the other one is located further upstream in
the promoter and is an overlap of a potential B-MYB-
binding site with a CHR-like element. It was suggested
that an E2F4/p130-containing DREAM complex binds
to the CDE/CHR region in quiescent cells, whereas in S
phase after the shift from E2F4/p130 to B-MYB, the then
formed MMB complex would bind to the upstream
B-MYB/CHR-like site (51). However, we tested the
upstream CHR-like site in the human CDC2 promoter
for function in reporter luciferase assays and found that
mutation of this element did neither change cell cycle-
dependent regulation nor general promoter activity signiﬁ-
cantly. Observations from the report show that LIN54
cannot easily be produced in recombinant form to be
tested for in vitro binding in EMSAs (51). If binding of
LIN54 to a non-functional CHR-like site is similar to its
afﬁnity to the established functional CHR, one may
suggest awaiting the results from more experiments to
either establish that LIN54 binds CHRs or identify some
other DREAM component to establish the contact with
the DNA in CDE/CHR-controlled promoters.
Another important issue related to DREAM binding is
the relative contribution of CDE and CHR elements. The
human cyclin B2 promoter does not have a functional
CDE and DREAM binding is exclusively dependent on
the CHR (Figures 2 and 3). Mutation of the CDE in the
mouse cyclin B2 promoter led to a small deregulation of
cell cycle-dependent transcriptional control caused by a 2-
to 3-fold increase of activity over background in G0 and
early G1 phase. In the same experiment, the wild-type
mouse cyclin B2 promoter yielded a regulation of about
30- to 40-fold when activity is measured in G2/M relative
to reporter activity in G0 and early G1 (Figure 4).
Comparing DREAM binding of the CDE mutant with
binding to the wild-type mouse promoter shows a
slightly reduced protein binding to the mutant promoter
(Figure 2A). In the case of the human cyclin B2 promoter
with a lack of a functional CDE, mutation of the corres-
ponding region does not inﬂuence promoter activity in
G0/G1 and DREAM binding is also not altered in
pull-down assays. Furthermore, the small functional con-
tribution of the CDE in the mouse cyclin B2 gene matches
well with the observation of the intact CDE supporting
binding of the DREAM complex to the CHR. Taken
together, the data from functional assays are consistent
with DREAM-binding results.
Interestingly, cyclin B2 CHR mutant reporter activity
does not reach the maximum in G2 seen with the wild-type
constructs, which would be expected if cell cycle-
dependent regulation would only be a result of repression
early in the cell cycle. Although a substantial part of
general promoter activity is likely due to NF-Y activating
the genes through the CCAAT-boxes (4), our current ob-
servation leads to the conclusion that full activation of the
promoter is not possible when the CHR is mutated
(Figure 4). This loss of activation for the short mCcnb2
construct is  3-fold. Taken together, the data prove not
only a strong repressive function for the CHR, but also a
smaller but detectable role in the activation of cyclin B2
promoters. As we were able to show that DREAM can
bind to the CHR without the necessity of the interaction
of E2f4 with an E2f-binding site, we wondered if the
MMB complex might bind to the same sequence without
a direct interaction of B-myb with a Myb-binding site.
This hypothesis would be consistent with the detected ac-
tivation of the cyclin B2 promoters through the CHR.
Prompted by these indicators, we tested B-myb binding.
B-myb was detected at the human and mouse cyclin B2
promoters in pull-down experiments using extracts from
proliferating NIH3T3 cells (Figure 5A). In both pro-
moters, binding depends only on a functional CHR.
Mutation of the CDE region does not reduce binding of
B-myb. Because the CHR is not related to canonical
Myb-binding sites, it is likely that B-myb is recruited to
the CHR by components of the MuvB-core. As it is not
possible to discriminate if components of the MuvB-core
are parts of DREAM or MMB, we made use of F9 cells
that were shown not to possess the DREAM complex
even in early G1 (34). Indeed, we were able to show that
B-myb together with other MMB proteins binds to the
CHR elements of cyclin B2 promoters independently of
the CDE (Figure 5B). A reduction of activity of the
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CHR elements after B-myb knockdown (Figure 5C)
further support the hypothesis that MMB can activate
cyclin B2 expression by binding to the CHR. It is highly
likely that the effect is directly mediated by an interaction
of MMB with the cyclin B2 promoter through the CHR
and not by a shift in cell cycle phases after B-myb
knockdown, because RNAi of B-myb provokes a partial
arrest of cells in G2/M (52,34), which would lead to an
increase and not to a reduction of cyclin B2 promoter
activity due to the cell cycle shift. Consistent with these
observations, it was shown by microarray analyses that a
knockdown of the MMB component Lin9 in F9 cells also
leads to a 2-fold reduction of cyclin B2 mRNA (34).
These results provide a ﬁrst link between the CHR and
activation of promoters in S, G2 and M phases. At ﬁrst
glance, activation through CHR sites in the later phases of
the cell cycle stands in contrast to the original observation
made by in vivo footprinting that CDE/CHR sites are not
occupied by protein when the promoters get activated (6).
However, clear-cut results by these footprints can only be
obtained for the CDE sites carrying several guanines.
CHRs mostly contain only one guanine or none at all.
Interestingly, an adenine gave a weak signal while the
only guanine in the cyclin A promoter did not yield a dif-
ferential footprint during the cell cycle (6). Taken together
with our observations, this may lead to a model by which
CDE/CHR tandem elements are occupied in G0/G1 by
DREAM, while the CDE is free of proteins and only
the CHR is occupied by MMB when the genes become
expressed.
Observations made analyzing the survivin gene hinted to
a classical binding of B-myb to B-myb consensus sites.
Knight et al. propose that four different Myb-binding
sites are necessary for binding of B-myb and Lin9 to the
survivin promoter. Mutation of each site resulted in loss of
protein binding as well as a decrease in promoter activity
(34). Schmit et al. have shown that several potential
Myb-binding sites are not necessary for binding
DREAM components from S phase extracts to the cdc2
promoter. Furthermore, they observed that the activating
DREAM complex seems to bind a different site in the
promoter than the repressing complex (51). One may
speculate that in some promoters the DREAM complex
is recruited to the DNA through E2F4 or B-myb to E2F/
CDE sites or Myb-binding sites, respectively, whereas in a
group of cyclin B2-like genes the CHR is sufﬁcient to
recruit DREAM through other components of the
complex. This could explain DREAM recruitment to pro-
moters that do not contain CHR elements (Figure 6).
Taken together, it appears that different mechanisms
mediate regulation of genes by the DREAM complex
even if promoters share common features like CDEs,
CHRs and CCAAT-boxes. In addition, other transcrip-
tion factors like FoxM1, ZNF143, c-Met and c-Myb
have been shown to participate at least in part
in activating genes expressed in S, G2 and M phases
(53–56). Activation by transcription factors that do not
bind through the CHR could be an explanation why the
Ube2c promoter with a mutated CHR still shows a
moderate cell cycle-dependent regulation in synchronized
NIH3T3 cells (Figure 7B). Indeed, it had been shown that
transcription of the Ube2c gene is activated by the factors
EWS/FLI1, cdc42, c-MYC and v-ABL (40). Our current
model for CHR-dependent regulation is that transcrip-
tional repression of CHR-containing promoters may be
a general mechanism, whereas activation in S, G2 and M
phases may be regulated by a complex interplay of differ-
ent transcription factors that could vary for many sub-
groups of cell cycle-regulated genes. This model could
also explain why most genes differ in their exact timing
of expression during the cell cycle.
With a bioinformatic approach, we were able to identify
a subgroup of DREAM complex-binding promoters con-
taining phylogenetically conserved CHR elements close to
the transcriptional start site. With 18.8% of genes con-
forming the selection criteria from the group of all
DREAM complex-binding promoters, CHR-containing
promoters are strongly enriched in comparison to the
control group.
We used a very stringent approach to identify pro-
moters containing CHR elements to reduce the number
of false calls. Only four published CHR-sequences,
namely TTTGAA, TTTAAA, TAGGAA and CTTGAA
(6,57,58) were used as templates for the analyses.
Interestingly, the CHR with the sequence TTTGAA,
which is mostly found in functionally characterized
CDE/CHR-regulated promoters to date, with its inverse
counterpart TTCAAA are most frequently observed with
about two-thirds of the hits among the four sequences
used for the bioinformatic search. More importantly, all
previously described experimentally validated CHR
elements appear in the list of CHR-containing promoters
(Supplementary Table S2). In addition, the predicted
inverse CHR in the Ube2c promoter was shown to be ne-
cessary for cell cycle-dependent regulation and DREAM/
MMB binding (Figure 7). This indicates that the param-
eters are adequate also for the identiﬁcation of further
previously unknown CHR elements. However, we
cannot rule out that some of the newly identiﬁed CHR
elements are not functional or are part of DNA
elements binding other transcription factors than
DREAM proteins. Furthermore, it is likely that there
are additional CHR elements in promoters binding the
DREAM complex that have not been identiﬁed in our
screen since we used only four experimentally veriﬁed
CHR sequences for the analysis. Recent observations
indicate that additional functional CHRs with variant
CHR sequences exist which would have to be included
in a more complex search in the future (our unpublished
data). Furthermore, we were able to show that promoters
from the control group that have not been detected in the
original screen as DREAM-binding proteins (19) indeed
bind the DREAM complex. However, such genes like
Reep4, Dzip1 and Rtkn2 were only identiﬁed among the
genes that possess evolutionary conserved CHR se-
quences, which again suggests a correlation between
DREAM-binding and CHR elements (Figure 6B).
Taken together, there will be even more promoters binding
DREAM that may contain CHRs than the genes we un-
covered by the current analyses. Even though the bioinfor-
matic analyses have not detected every functional CHR,
Nucleic Acids Research,2012, Vol.40, No. 4 1575the data strongly suggest that CHR elements play an im-
portant role in binding of the DREAM complex in many
promoters.
In summary, we identify the DREAM complex to bind
mainly through the CHR to mammalian cyclin B2 pro-
moters in G0. In the human cyclin B2 promoter, binding
of E2F4 to the E2F-related CDE site is not required for
DREAM function. However, a functional CDE as
observed in the mouse cyclin B2 promoter is able to en-
hance binding of DREAM proteins. The CHR element,
and in association with it likely also the DREAM
proteins, confers repression in G0 and participates in the
activation of CDE/CHR promoters in later cell cycle
phases. Binding of B-myb to the CHR of the cyclin B2
promoter could provide a link to the activation in S, G2
and M phases. Bioinformatic analyses suggest that many
more genes binding the DREAM complex in their pro-
moters possess phylogenetically conserved CHR
elements. These ﬁndings indicate that the CHR is a
central element in transcriptional regulation by the
DREAM and MMB complexes.
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